Royalty Pharma plc

As of June 30, 2026, Royalty Pharma Plc Class A carries a market capitalization of 343.99B, placing it among publicly traded companies globally. Its enterprise value stands at 522.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Royalty Pharma Plc Class A's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Royalty Pharma Plc Class A has 445.75M shares outstanding.

As of June 30, 2026, Royalty Pharma Plc Class A trades at a trailing price-to-earnings ratio of 23.67. The price-to-sales ratio is 7.61, and the price-to-book ratio stands at 2.88.

As of June 30, 2026, Royalty Pharma Plc Class A trades at an EV/EBITDA multiple of 19.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 11.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.76 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Royalty Pharma Plc Class A trades at an EV/FCF ratio of 8.95, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 522.00B versus a market cap of 343.99B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Royalty Pharma Plc Class A maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.58, indicating elevated leverage, while an interest coverage ratio of 4.20 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Royalty Pharma Plc Class A posted a return on equity (ROE) of 12.37, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.34 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.27, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.54, useful for judging operating efficiency across full business cycles. The company generates approximately 444.19M in revenue per employee across its workforce of 99.75, a quick read on workforce productivity versus industry peers.

As of the close on October 20, 2026, Royalty Pharma Plc Class A's stock has gained approximately 57.56% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Royalty Pharma Plc Class A generated 44.31B in revenue and converted that into 14.24B in net income, yielding earnings per share of 42.30. EBITDA reached 26.50B, while operating income came in at 27.63B.

As of June 30, 2026, Royalty Pharma Plc Class A holds 30.16B in cash and equivalents against 156.58B in total debt, resulting in a net debt position of 142.39B. Total book value stands at 119.38B, with working capital of 19.81B providing operational flexibility.

Royalty Pharma Plc Class A produced 52.00B in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of 62.35 and net profit margin of 32.14 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Royalty Pharma Plc Class A paid dividends of 15.96 per share. The dividend payout ratio of 21.17 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 12.09, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.44, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Royalty Pharma Plc Class A shareholders.

As of June 30, 2026, Royalty Pharma Plc Class A has an Altman Z-Score of 1.84, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.